Inresa Drugs

Name

Inresa Drugs

Legal name

Inresa Arzneimittel GmbH

Website

https://inresa.de

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Inresa Arzneimittel GmbH is a German pharmaceutical company that manufactures and distributes generic hospital injectables and licensed medical products to German hospitals and pharmacies under its own regulatory approval (§13 AMG).

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Sterile Injectable Generics (HLAIABAC)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic Hospital & Institutional Products (HLAIABAL), Authorized Generics (HLAIABAK), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

Keywords

• Generic pharmaceuticals
• Hospital pharmaceutical supply
• Injectable medications
• Licensed medical products
• Pharmaceutical distribution Germany

Headquarters

HQ city

Freiburg Im Breisgau

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Generic pharmaceutical sales: Sale of generic pharmaceutical preparations under their own regulatory approval to hospitals in Germany. Products include injectables, IV solutions, and other hospital-grade medications.
2. Licensed product distribution: Distribution of medical products and pharmaceuticals under license agreements with other pharmaceutical manufacturers.
3. Single import services (§73.3 AMG): Individual import of medicines according to §73.3 AMG for German pharmacies, providing access to diverse range of compliant pharmaceutical products.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Inresa Arzneimittel GmbH manufactures and distributes generic pharmaceutical preparations — primarily injectable and intravenous medications — under its own regulatory approval (manufacturing authorization per §13 AMG) to German hospitals. The company also distributes licensed medical products and pharmaceuticals from other manufacturers, and provides individual import services under §73.3 AMG for German pharmacies requiring access to medicines not otherwise available in Germany.

Product overview

Inresa Arzneimittel GmbH is a pharmaceutical company specializing in hospital supplies of generic preparations and licensed medical products. The product portfolio comprises injectable neuromuscular blocking agents (Pancuronium, Vecuronium, Rocuronium, Sugammadex), anaesthetics (Esketamin, Ketamin), antibiotics (Erythromycin i.v.), antifungals (Micafungin), and other hospital-critical medications including Terlipressin, Dexketoprofen, Somatostatin, and the formulation vehicle InOrpha. The company also offers individual import of medicines for German pharmacies under §73.3 AMG.

Differentiator

Problem solved

Functional benefit

Products and services

• Pancuronium Inresa Injection solution for intravenous (I.V.) administration, used as a neuromuscular blocking agent for hospital use.
• Esketamin Inresa 25 mg/ml (2 ml / 10 ml) Anaesthetic agent for intravenous or intramuscular application for hospital use.
• Ketamin Inresa 2 ml Anaesthetic for intravenous or intramuscular injection or infusion after dilution.
• Erythromycin Inresa i.v. 1 g Antibiotic preparation for intravenous infusion, supplied to hospitals.
• Micafungin Inresa 50 mg & 100 mg Antifungal agent for intravenous application after reconstitution and dilution.
• Vecuronium Inresa 10 mg Neuromuscular blocking agent for intravenous injection or infusion.
• Rocuronium Inresa 10 mg/ml (10 ml) Neuromuscular blocking agent for intravenous administration.
• Sugammadex Inresa 100 mg/ml (2 ml) Selective relaxant binding agent for reversal of neuromuscular blockade.
• Terlipressin Inresa 1 mg Injektionslösung Injection solution used for treatment of variceal bleeding and hepatorenal syndrome.
• Dexketoprofen Inresa Non-steroidal anti-inflammatory drug (NSAID) for pain relief, administered intravenously after reconstitution and dilution.
• Somatostatin 3 mg Inresa Hormonal preparation administered as a bolus, used for treatment of variceal bleeding and acute pancreatitis.
• InOrpha Flavored suspension vehicle (aromatisiertes Suspensionsvehikel) for formulation of oral solutions and suspensions, used as a proprietary pharmaceutical excipient.
• Einzelimport für Deutsche Apotheken (§73.3 AMG) Individual import service for German pharmacies under §73.3 of the German Medicines Act (AMG), providing access to a diverse range of compliant pharmaceutical products not otherwise available in Germany.
• Licensed Pharmaceutical Distribution Distribution of medical products and pharmaceuticals under license agreements with other pharmaceutical manufacturers, supplied to hospitals and pharmacies.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• CuraMED Pharma GmbH (historical)historicalOthersCuraMED Pharma GmbH was sold prior to Inresa's founding in 1993. The founders Bruno C. Wassmer, Gernot Harrant, and Lutz Mothes came from 30 years in the pharmaceutical industry and the sale of CuraMED Pharma GmbH.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Rotexmedica GmbH: Rotexmedica is a German-based manufacturer of generic injectable pharmaceuticals. Direct competitor to Inresa in the German hospital injectable generics market with similar product categories and customer base.
• Hameln Pharma GmbH: Hameln Pharma is a German manufacturer of generic injectable pharmaceuticals supplying hospitals globally. Highly comparable to Inresa given the shared focus on sterile injectable generics, GMP manufacturing, and hospital-channel distribution.
• Hikma Pharmaceuticals PLC: Hikma is a multinational generic injectable manufacturer with significant European hospital presence. Directly comparable to Inresa through its focus on sterile injectable generics for institutional customers.

Broad incumbents

• Hexal AG: Hexal is a major German generics manufacturer owned by Sandoz/Novartis. Broad incumbent in the German generics market with deep pharmacy and hospital relationships overlapping Inresa's customer base.
• Fresenius Kabi: Fresenius Kabi is a global leader in hospital generics, infusion therapies, and clinical nutrition. Operates broadly in the same hospital injectable generics space as Inresa with much larger scale and global reach.
• Stada Arzneimittel AG: Stada is one of the largest generic pharmaceutical companies in Germany, offering a broad portfolio including injectables. Larger incumbent serving overlapping German pharmacy and hospital channels.
• B. Braun Melsungen AG: B. Braun is a major German medical and pharmaceutical company with a large hospital injectables and infusion solutions portfolio. Broad incumbent in the same hospital-channel generic injectable space Inresa serves.
• ratiopharm (Teva): ratiopharm is one of Germany's best-known generic pharmaceutical brands, owned by Teva. Serves overlapping pharmacy and hospital channels with a broad generics portfolio.

Emerging players

• Aurobindo Pharma: Aurobindo is a major Indian-headquartered generic pharmaceutical manufacturer with growing injectable generics presence in European markets. Emerging player competing with Inresa in selected injectable categories.

Others

• Aenova Holding GmbH: Aenova is a German-headquartered pharmaceutical contract development and manufacturing organization (CDMO). Adjacent to Inresa's GMP manufacturing operations as a comparable German pharma manufacturing services peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/InresaGmbH
• LinkedInlinkedin.com/company/inresa-arzneimittel-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inresa Drugs